FDA Approves DIACOMIT — BIOCODEX, INC.

BioCodex, Inc. secured FDA clearance for Diacomit to treat refractory pediatric epileptic encephalopathies, allowing the company to capitalize on the specialized neurology market. This approval significantly strengthens BioCodex's financial outlook by addressing a critical unmet need for patients with Lennox-Gastaut and Dravet syndromes.